The Ghanaian government is set to establish two pharmaceutical and biomanufacturing hubs in the Eastern and Central Regions from 2027, as part of a $1 billion initiative. This project aims to reduce the country's dependence on imported medicines and position Ghana as a major pharmaceutical manufacturing centre in West Africa. The facilities will operate as special economic zones, providing infrastructure for local and international pharmaceutical companies.
According to the 2027 Budget Statement, a state-owned special purpose vehicle is expected to commence construction of the hubs in 2027. The Presidential Coordinator of the Ghana Pharmaceutical Hub, Dr Bernice Makafui Brempong, described the initiative as a major opportunity to transform the country's pharmaceutical industry. She emphasized the government's commitment to building a strong domestic manufacturing base capable of meeting local demand and serving markets across the continent.
Dr Brempong estimated that Ghana spends approximately GH¢5 billion annually importing pharmaceutical products, mainly from India and China. Expanding local production would help retain a significant portion of the expenditure within the economy, creating jobs and generating foreign exchange for the country. The project falls under the government's $1 billion Pharmaceutical and Biomanufacturing Compact, which forms part of its New Economy programme.
By 2030, the initiative aims to increase the proportion of essential medicines manufactured locally to between 60 and 80 per cent, while developing the capacity to supply other African countries. The hubs are expected to strengthen local supply chains, promote technology transfer, and equip Ghanaian professionals with the skills required to support a competitive pharmaceutical industry.
Dr Brempong said the initiative was also intended to support growing demand for medicines arising from the government's healthcare programmes, including Free Primary Healthcare and the Ghana Medical Trust Fund. The pharmaceutical hub, approved as a Presidential National Legacy Flagship Initiative, would provide an integrated framework for organising the pharmaceutical market, securing demand, financing production capacity, and supplying medicines to Ghana and other markets.
Chairperson for the occasion, Dr Martha Gyansa-Lutterodt, emphasized the importance of a dependable pharmaceutical supply system for the success of the government's healthcare reforms. She noted that the Free Primary Healthcare programme could only achieve its objectives if patients had consistent access to the medicines they needed, used them safely, and completed their treatment without interruptions.
Dr Gyansa-Lutterodt cautioned that expanding access to free healthcare must not result in medicine shortages, emphasizing the need for a competent pharmaceutical workforce and systems that prioritise reliable supply, patient safety, and quality care. The government aims to protect the livelihoods of existing players in the pharmaceutical value chain, including importers, distributors, and their employees, as the country transitions towards greater local production.
Key points
- The initiative aims to increase local production of essential medicines to 60-80% by 2030.
Reporting sources
- Ghana to establish US$1bn... · ModernGhana